Market capitalization | $10.13m |
Enterprise Value | $-11.81m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.33 |
EV/Sales (TTM) EV/Sales | -1,181.00 |
P/S ratio (TTM) P/S ratio | 1,013.00 |
P/B ratio (TTM) P/B ratio | 0.50 |
Revenue (TTM) Revenue | $10.00k |
EBIT (operating result TTM) EBIT | $-40.88m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
4 Analysts have issued a GlycoMimetics, Inc. forecast:
4 Analysts have issued a GlycoMimetics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.01 0.01 |
-
|
|
Gross Profit | -0.31 -0.31 |
70%
70%
|
|
EBITDA | -41 -41 |
6%
6%
|
EBIT (Operating Income) EBIT | -41 -41 |
4%
4%
|
Net Profit | -39 -39 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Head office | United States |
CEO | Harout Semerjian |
Employees | 35 |
Founded | 2003 |
Website | www.glycomimetics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.